MRC Lifecourse Epidemiology Centre, University of Southampton, Tremona Road, Southampton, SO16 6YD, UK.
European Medicines Agency, Amsterdam, The Netherlands.
Aging Clin Exp Res. 2022 Sep;34(9):1985-1995. doi: 10.1007/s40520-022-02176-y. Epub 2022 Jul 21.
Hand osteoarthritis is the most common joint condition and is associated with significant morbidity. It is of paramount importance that patients are thoroughly assessed and examined when complaining of hand stiffness, pain, deformity or disability and that the patient's concerns and expectations are addressed by the healthcare professional. In 2019 the American College of Rheumatology and Arthritis Foundation (ACR/AF) produced guidelines which included recommendations for the treatment of hand osteoarthritis. An ESCEO expert working group (including patients) was convened and composed this paper with the aim to assess whether these guidelines were appropriate for the treatment of hand osteoarthritis therapy in Europe and whether they met with the ESCEO patient-centered approach. Indeed, patients are the key stakeholders in healthcare and eliciting the patient's preference is vital in the context of an individual consultation but also for informing research and policy-making. The patients involved in this working group emphasised the often-neglected area of aesthetic changes in hand osteoarthritis, importance of developing pharmacological therapies which can alleviate pain and disability and the need of the freedom to choose which approach (out of pharmacological, surgical or non-pharmacological) they wished to pursue. Following robust appraisal, it was recommended that the ACR/AF guidelines were suitable for a European context (as described within the body of the manuscript) and it was emphasised that patient preferences are key to the success of individual consultations, future research and future policy-making.
手骨关节炎是最常见的关节疾病,与显著的发病率有关。当患者抱怨手部僵硬、疼痛、畸形或残疾时,对其进行彻底的评估和检查至关重要,并且医疗保健专业人员应解决患者的关切和期望。2019 年,美国风湿病学会和关节炎基金会(ACR/AF)制定了指南,其中包括对手骨关节炎治疗的建议。一个 ESCEO 专家工作组(包括患者)被召集起来,撰写了这篇论文,目的是评估这些指南是否适用于欧洲对手骨关节炎治疗的方法,以及它们是否符合 ESCEO 以患者为中心的方法。实际上,患者是医疗保健的关键利益相关者,在个体咨询中了解患者的偏好至关重要,但在告知研究和决策方面也是如此。参与该工作组的患者强调了手骨关节炎中经常被忽视的美容变化领域,开发可以缓解疼痛和残疾的药物治疗的重要性,以及选择他们希望采用的治疗方法(药物、手术或非药物)的自由的必要性。经过严格评估,建议 ACR/AF 指南适用于欧洲背景(如本文所述),并强调患者的偏好是个体咨询、未来研究和未来决策成功的关键。